Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab + anlotinib + platinum-doublet chemotherapy as first-line treatment for advanced pulmonary sarcomatoid carcinoma
ChiCTR2400086977Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in lung sarcomatoid carcinoma (PSC) and non-small cell lung cancer (NSCLC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
lung sarcomatoid carcinoma (PSC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086977.